Biotron Limited
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.
Biotron Limited (BITRF) - Total Liabilities
Latest total liabilities as of December 2025: $1.16 Million USD
Based on the latest financial reports, Biotron Limited (BITRF) has total liabilities worth $1.16 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biotron Limited - Total Liabilities Trend (2001–2025)
This chart illustrates how Biotron Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biotron Limited Competitors by Total Liabilities
The table below lists competitors of Biotron Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Finlay Minerals Ltd
OTCQB:FYMNF
|
USA | $3.96 Million |
|
WiSA Technologies Inc
NASDAQ:WISA
|
USA | $13.99 Million |
|
Refined Metals Corp.
PINK:RFMCF
|
USA | $891.36K |
|
Bioscience Animal Health PCL
BK:BIS
|
Thailand | ฿463.53 Million |
|
Binect AG
XETRA:MA10
|
Germany | €3.31 Million |
|
SE-Education Public Company Limited
BK:SE-ED
|
Thailand | ฿1.28 Billion |
|
Evolva Holding SA
PINK:ELVAF
|
USA | $945.30K |
|
Scandium Canada Ltd
PINK:SCDCF
|
USA | $2.11 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Biotron Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biotron Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biotron Limited (2001–2025)
The table below shows the annual total liabilities of Biotron Limited from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $428.51K | -41.90% |
| 2024-06-30 | $737.51K | -23.38% |
| 2023-06-30 | $962.49K | +18.31% |
| 2022-06-30 | $813.57K | +75.52% |
| 2021-06-30 | $463.51K | -45.67% |
| 2020-06-30 | $853.19K | +104.11% |
| 2019-06-30 | $418.00K | +23.78% |
| 2018-06-30 | $337.70K | -45.49% |
| 2017-06-30 | $619.51K | +78.89% |
| 2016-06-30 | $346.32K | -26.81% |
| 2015-06-30 | $473.18K | -0.31% |
| 2014-06-30 | $474.64K | +21.37% |
| 2013-06-30 | $391.08K | +103.50% |
| 2012-06-30 | $192.18K | -21.34% |
| 2011-06-30 | $244.32K | +74.16% |
| 2010-06-30 | $140.29K | -36.90% |
| 2009-06-30 | $222.33K | -47.56% |
| 2008-06-30 | $423.94K | +160.05% |
| 2007-06-30 | $163.02K | -48.75% |
| 2006-06-30 | $318.11K | +112.24% |
| 2005-06-30 | $149.88K | -2.25% |
| 2004-06-30 | $153.33K | +3.55% |
| 2003-06-30 | $148.08K | +3.63% |
| 2002-06-30 | $142.90K | +28.22% |
| 2001-06-30 | $111.45K | -- |